Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

DPP-4 as a Possible Biomarker of Inflammation Before Abdominal Surgery for Chronic Pathology: Our Experience with Elective Cholecystectomy.

Valencia-Sánchez L, Almendra-Pegueros R, R-Valdez LJD, Esmer-Sánchez D, Medina Ú, Gordillo-Moscoso A.

Medicina (Kaunas). 2019 May 16;55(5). pii: E148. doi: 10.3390/medicina55050148.

2.

Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus.

Cho EH, Kim SW.

Diabetes Metab J. 2019 Feb;43(1):97-104. doi: 10.4093/dmj.2018.0030. Epub 2018 Oct 8.

4.
5.

Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.

Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.

Biochem Biophys Res Commun. 2014 Jan 17;443(3):828-33. doi: 10.1016/j.bbrc.2013.12.049. Epub 2013 Dec 14.

PMID:
24342619
6.

Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus.

Tanaka S, Kanazawa I, Notsu M, Sugimoto T.

Diabetes Res Clin Pract. 2016 Jun;116:1-6. doi: 10.1016/j.diabres.2016.04.027. Epub 2016 Apr 23.

PMID:
27321309
7.

Dipeptidyl peptidase-4 inhibitors: multitarget drugs, not only antidiabetes drugs.

Zhao Y, Yang L, Zhou Z.

J Diabetes. 2014 Jan;6(1):21-9. doi: 10.1111/1753-0407.12063. Epub 2013 Jun 19. Review.

PMID:
23683065
8.

Persons with latent autoimmune diabetes in adults express higher dipeptidyl peptidase-4 activity compared to persons with type 2 and type 1 diabetes.

Duvnjak L, Blaslov K, Vučić Lovrenčić M, Knežević Ćuća J.

Diabetes Res Clin Pract. 2016 Nov;121:119-126. doi: 10.1016/j.diabres.2016.09.013. Epub 2016 Sep 21.

PMID:
27693949
9.

Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes.

Duvnjak L, Perković MN, Blaslov K.

J Diabetes Complications. 2017 Jan;31(1):218-222. doi: 10.1016/j.jdiacomp.2016.08.022. Epub 2016 Aug 28.

PMID:
27625045
10.

Systemic inflammation and immune response after laparotomy vs laparoscopy in patients with acute cholecystitis, complicated by peritonitis.

Sista F, Schietroma M, Santis GD, Mattei A, Cecilia EM, Piccione F, Leardi S, Carlei F, Amicucci G.

World J Gastrointest Surg. 2013 Apr 27;5(4):73-82. doi: 10.4240/wjgs.v5.i4.73.

11.

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.

Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K, Somogyi A.

PLoS One. 2010 Aug 18;5(8):e12226. doi: 10.1371/journal.pone.0012226.

12.

Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome.

Malin SK, Huang H, Mulya A, Kashyap SR, Kirwan JP.

Peptides. 2013 Sep;47:142-7. doi: 10.1016/j.peptides.2013.07.008. Epub 2013 Jul 17.

13.
14.

Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity.

Kahraman S, Eroglu Altinova A, Elgun S, Yalcin MM, Aktas Yilmaz B, Ozkan C, Akturk M, Balos Toruner F.

Gynecol Endocrinol. 2019 Mar 21:1-5. doi: 10.1080/09513590.2019.1581165. [Epub ahead of print]

PMID:
30896318
15.

Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.

Kim YG, Kim S, Han SJ, Kim DJ, Lee KW, Kim HJ.

J Diabetes Res. 2018 Apr 10;2018:5246976. doi: 10.1155/2018/5246976. eCollection 2018.

16.

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.

Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S.

Circulation. 2011 Nov 22;124(21):2338-49. doi: 10.1161/CIRCULATIONAHA.111.041418. Epub 2011 Oct 17.

17.

Serum levels of pigment epithelium-derived factor (PEDF) are inversely associated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.

Tahara N, Yamagishi S, Matsui T, Nishino Y, Honda A, Tahara A, Igata S, Fukumoto Y.

Int J Cardiol. 2015 Apr 1;184:14-6. doi: 10.1016/j.ijcard.2015.02.010. Epub 2015 Feb 10.

PMID:
25705004
18.

The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: A cohort study.

Gamble JM, Donnan JR, Chibrikov E, Twells LK, Midodzi WK, Majumdar SR.

Diabetes Res Clin Pract. 2018 Feb;136:159-167. doi: 10.1016/j.diabres.2017.12.008. Epub 2017 Dec 16.

19.

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, Vilsbøll T.

Eur J Endocrinol. 2006 Sep;155(3):485-93.

PMID:
16914604
20.

Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans.

Tahara N, Yamagishi S, Takeuchi M, Tahara A, Kaifu K, Ueda S, Okuda S, Imaizumi T.

Clin Biochem. 2013 Mar;46(4-5):300-3. doi: 10.1016/j.clinbiochem.2012.11.023. Epub 2012 Dec 4.

PMID:
23219738

Supplemental Content

Support Center